Long–Term Observational Comparison of Risperidone and Olanzapine in Bipolar Disorder
S. NASSIR GHAEMI M.D.DOUGLAS J. HSU B.S.
KLARA J. ROSENQUIST B.S.
JACOB J. KATZOW M.D.
REDERICK K. GOODWIN M.D.
pages: 69 - 73
- DOI: 10.1080/10401230490453103
- Version of record first published: 2004
Full Text
Abstract:
To compare long-term effectiveness and safety of risperidone versus olanzapine as adjunctive maintenance treatments of bipolar disorder. Retrospective observational chart review of 29 outpatients with bipolar or schizoaffective disorder (type I =15, type II =3, NOS =5, schizoaffective =6) who received risperidone or olanzapine added to lithium or valproate>3 months. Acute indications were depression (n =8), manic/hypomanic/mixed states (n =8), rapid cycling (n =6), other indications (n =6), and prophylaxis (n =1). Logistic regression models adjusted for potential confounding factors (i.e., severity of illness, comorbid substance abuse, diagnostic subtype). Overall duration of follow-up was 65.9 ±70.1 weeks. Mild to moderate response was similar in the risperidone and olanzapine groups after adjusting for potential confounders (OR =0.91, 95% CI [0.05, 16.17]). Somewhat greater adjusted moderate to marked response (OR>3.60, 95% CI [0.31,>42.00]) and longer duration of treatment (HR =0.52, 95% CI [0.22, 1.22]) occurred in the risperidone group, but were still compatible with the null hypothesis. Weight gain occurred more frequently with olanzapine (57%) than risperidone (13%). EPS was similar, and tardive dyskinesia did not occur. Risperidone and olanzapine appeared to have similar real-world maintenance effectiveness for bipolar disorder, but differed somewhat in side effects.